Adam Bressler is an Infectious Disease physician affiliated with Northeast Georgia Medical Center. OpenAlex indexes 33 publications with 1,256 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1211 Sherwood Park Dr NE Ste B
Gainesville, GA 305013444
Telephone
770-219-8420Provider last certified this registry record 17 May 2024.
Clinical trials
- Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
Sponsor: Romark Laboratories L.C.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202517 payments$12,968openpaymentsdata.cms.gov ↗
- Cumberland Pharmaceuticals, Inc.Program year20252 payments
- ViiV Healthcare CompanyProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor35%Juluca34%Dovato23%Tivicay19%Cabenuva14%Isentress Hd11%Part D<11 patientsCephalosporin Antibacterial14.5%Ceftriaxone58%Cefazolin Sodium42%Part D<11 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Culture-Negative Infective Endocarditis Presenting as ANCA-Positive Glomerulonephritis
American Journal of Case Reports
2026 - Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Infectious Diseases and Therapy
2024 - Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Infectious Diseases and Therapy
2024 - Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection
Journal of Clinical Microbiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Habib Samady, MD
Northeast Georgia Medical Center
Stephane Rinfret
Northeast Georgia Medical Center
Ronnie Ramadan, MD
Northeast Georgia Medical Center
Nancy Stead, MD
Northeast Georgia Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”